SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

TBOPP

Cat. No.:	HY-124711
CAS No.:	1996629-79-8
Molecular Formula:	$C_{24}H_{21}F_3N_2O_4S$
Molecular Weight:	490.49
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (203.88 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0388 mL	10.1939 mL	20.3878 mL
	5 mM	0.4078 mL	2.0388 mL	4.0776 mL
	10 mM	0.2039 mL	1.0194 mL	2.0388 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.24 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TBOPP is a selective inhibitor of DOCK1 with an IC_{50} of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (K_d of 7.1 μM), has anti-tumor activity for broader types of tumors[1].

IC_{50} & Target

IC50: 8.4 μM (DOCK1); Kd: 7.1 μM (DOCK1 DHR-2 domain)[1]

In Vitro

TBOPP (12.5 μM; 3 days; 3LL cells) treatment inhibits DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	3LL cells
Concentration:	12.5 μM
Incubation Time:	3 days
Result:	Inhibited cell viability.

In Vivo

TBOPP (0.67 mg per mouse; administrated on days 0, 1, 3, and 5; for 2 weeks; C57BL/6 mice) treatment effectively suppresses metastasis of cancer cells in vivo and the number of lymphocytes in the spleen is not changed, the body weight is also unchanged between TBOPP-treated and non-treated mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (6- to 8-week-old) with ex-3LL cells[1]
Dosage:	0.67 mg per mouse
Administration:	Administrated on days 0, 1, 3, and 5; for 2 weeks
Result:	The lung metastasis was significantly suppressed.

REFERENCES

[1]. Tajiri H, et al. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Cell Rep. 2017 May 2;19(5):969-980.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA